Bookmarks
ID 212-3: Estimating inequalities in burden of illness in patients with Alzheimer’s disease
Safe People
Organisation name
Lane Clark & Peacock LLP
Applicant name(s)
Funders/ Sponsors
Safe Projects
Project ID
ID 212-3
Lay summary
Understanding the impact of Alzheimer’s disease on individuals and on the healthcare system will support the development of interventions and treatments to reduce the progression of Alzheimer’s disease.
Public benefit statement
With current trends in population ageing, the number of people living with Alzheimer’s disease has increased substantially in recent years and is expected to continue increasing. These older persons experience a wide range of negative impacts on their health as both a direct and indirect consequence of a reduction in memory, and changes in thinking and behaviour. As a result, healthcare providers such as the National Health Service are facing an increasing challenge in supporting patients to live Alzheimer’s disease with many patients having to self-fund specialist care due to a lack of support. Understanding the impact of Alzheimer’s disease on individuals and on the healthcare system will support the development of interventions and treatments to reduce the progression of Alzheimer’s disease. This is particularly challenging in Alzheimer’s disease given the variety in the course of the illness and the many conditions indirectly associated with Alzheimer’s disease. This complexity is best assessed through the analysis of large-scale health databases (such as Discover-NOW) that contain a rich variety of data. We will use Discover-Now to develop robust epidemiological analyses and statistical models that will improve our understanding of the health profiles of people living with Alzheimer’s disease and the potential impact of new treatments being developed to reduce the risk of Alzheimer’s disease progression. By repeating our analysis across important subgroups of groups we will aim to identify the populations with highest unmet need and who might benefit most from treatment. These findings can help to ensure that new treatments are developed that support Alzheimer’s disease patients with the highest unmet health needs, resulting in more equitable health outcomes for the population.
Other approval committees
Latest approval date
14/09/2023
Safe Data
Dataset(s) name
Safe Setting
Access type
TRE